In VitroActivity of Fusidic Acid (CEM-102, Sodium Fusidate) against Staphylococcus aureus Isolates from Cystic Fibrosis Patients and Its Effect on the Activities of Tobramycin and Amikacin against Pseudomonas aeruginosa and Burkholderia cepacia
2011 ◽
Vol 55
(5)
◽
pp. 2417-2419
◽
Keyword(s):
ABSTRACTWe tested the MICs of fusidic acid (CEM-102) plus other agents against 40 methicillin-resistantStaphylococcus aureus(MRSA) isolates from cystic fibrosis patients and the activities of fusidic acid with or without tobramycin or amikacin againstPseudomonas aeruginosa, MRSA, andBurkholderia cepaciaisolates from cystic fibrosis patients in a 24-h time-kill study. Fusidic acid was potent (MICs, 0.125 to 0.5 μg/ml; a single 500-mg dose of fusidic acid at 8 h averaged 8 to 12. 5 μg/ml with 91 to 97% protein binding) against all MRSA strains. No antagonism was observed; synergy occurred for one MRSA strain treated with fusidic acid plus tobramycin.
2012 ◽
Vol 56
(8)
◽
pp. 4422-4427
◽
Keyword(s):
2004 ◽
Vol 3
(3)
◽
pp. 159-163
◽
2011 ◽
Vol 55
(11)
◽
pp. 5004-5009
◽
Keyword(s):
2012 ◽
Vol 56
(5)
◽
pp. 2753-2755
◽
2012 ◽
Vol 56
(11)
◽
pp. 5528-5533
◽
Keyword(s):
2020 ◽
Vol 19
(1)
◽
pp. 14-23